Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What did it do?
Sports fans were itching for some fast paced rev rev revenue... and zoom zoom zoom went the stock price.
But the big voice in the sky was silent on the competition call. Sports fans love popcorn.. yummy yummy with the rev rev revs expectations....
What did it do.. make it in scale?!?? SAY .37 to $6.00USD for the viable option sill on the throttle??
The money still at the checkered flag.. Air is still smelling like hot fuel in the sun..
Smells like burnt rubber too....
Perhaps the track is bit more more open now it seems sports fans.
data accrued to date for the TLD 1433-2 open label study for
$TLTFF
The data accrued to date for the TLD 1433-2 open label study for the treatment of NMIBC, seems very encouraging, and Theralase may as well be heading towards fulfilling the necessary outcome requirements to apply for a “BTD from the FDA very soon. Dr. Vera Madzarevic Director Clinical Development & Quality Assurance, Theralase® NOVEMBER 2021
$TLTFF destroy various cancers
Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses
$TLTFF Sustained Momentum on the call.
TLTFF price was about 17 cents 10 SEPT 21
His call is getting traction.
Hey Doug Loe? Any update Mr Sir???
I recall Mr. Loe sayin Theralse was well patented until 2033!
Phase 2 pivatol is going very good.
September 10, 2021 Capital Research
It looks like one COPETITORS NMIBC NONRESPONSE HAS BEEN BACK BURNERED FOR MONTHS BUY THE FDA.. looks LIKE THEY HAVE TO RETOOL THE NMIBC NONRESPONSE TRIDE. Blew out the head gasket .. push her back to the shop boys.
Theralase is full speed ahead and funded.
India?!? ya say... mmmmm ok.... cool..
$TLTFF Cathy Wood As of November 29, 2021
Study II Preliminary Results
As of November 29, 2021, Study II has enrolled and provided the primary study treatment for 30 patients (including three patients from the Study treated at the Therapeutic Dose) for a total of 33 patients, demonstrating the following interim results:
Note: Significant clinical data is still pending in Study II and drawing conclusions from this interim clinical data set and assumptions should be done with caution, as Study II is still ongoing and new clinical data collected may or may not continue to support the current trend.
*Includes three (3) patients treated at the Therapeutic Dose form Phase Ib NMIBC Clinical Study (2-CR and 1- NR at 90, 180, 270, 360, 450 days)
An analysis of the Study II clinical data (with 3 patients from Study Ib) provides the following interim assessments:
7/10 patients (70.0%), who achieved a CR at 90 days continue to demonstrate CR at 180 days
In the total population of 33 patients (@ 90 days):
42.4% achieved Complete Response (“CR”)
12.1% achieved Partial Response (“PR”)
21.2% are Pending
24.2% achieved No Response (“NR”)
Hence, the potential for CR is up to 75.8%** for the interim clinical data analysis.
Note**: Assumes both PR and Pending data are clinically determined to be CR at a later assessment date.
In the total population of 18 patients (@ 90 days), who received the optimized treatment:
44.4% achieved CR
11.1% achieved PR
38.9% are Pending
5.6% achieved NR
Hence, the potential for CR is up to 94.4%***
Note***: Assumes both PR and Pending data are clinically determined to be CR at a later assessment date for the interim clinical data analysis.
In summary, for patients who received the primary optimized Study II Treatment versus the original Study II Treatment (90 days), there is a 5% increase in CR and a 77% decrease in NR
About Theralase® Technologies Inc.
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
So much power. They dialed it back for the first 12 patients in Phase 2 pivotal. Now they are getting the full dose in Phase 2 PIVOTAL! $TLTFF 67 % CR IN PHASE ONE STUDY FROM ONE TREATMENT.
SES* was the FDA NMIBC darling but they fell from grace. .37 to OVER SIX BUCKS A SHARE.
Keep my hopes up...Clementine!
Oh my darlin, oh my darlin...
Clementine.
One day she'll be com'n 'round the mountain when she comes.
My side wish is that the laser can be used to dull the war driven egos of our time.
Here's to hoping.
$TLTFF - AA-BTD safety$ CR rates. Hello Darlin!!
Theralase is the New FDA Darlin
SES* was the FDA NMIBC darling but they fell from grace. .37 to OVER SIX BUCKS A SHARE.
But then it was clear SES* treatments are not good enough. They fell fast and hard. The Market know they are not the FDA DARLIN!!
The market pivot is in progress.
Sept 1 2021 Research Capital Uddin TLTFF SESN
Uddin also commented on a recent event from competitor Sesen Bio, which on August 13 received a complete response letter (CRL) from the US FDA on a BLA for its Vicineum in BCG- unresponse NMIBC. Uddin related that Sesen aims to meet with the FDA in the fourth quarter of this year to get better clarity on next steps. The analyst said the announcement could open a potential window of opportunity for TLT, saying,
“On August 18th, a report by STAT News, which was based on SESN’s internal documents obtained by STAT, stated SESN’s pivotal trial with Vicineum had thousands of violations of study rules, investigator misconduct and worrying signs of toxicity SESN did not publicly disclose,” Uddin wrote.
SESNSept 1 2021 Research Capital Uddin TLTFF
0.32$ TO 6 over six bucks IS THE SESN CHART THAT BLEW OUT. That is the current market valuation for NMIBC treatment optimism?? Yes??
TLTFF the FDAs new Darlin.
SES* was the darling for a bit.
.32 USD to over SIX BUCKS A SHARE!!!. But then it was very clear to the market. SES* aint the FDA Darlin. Darlin im sorry you aint my darlin time for a breakup or really a big break down....
YEPPERS... have a peek at tlt and that non darlin 3 month chart....
One might consider it prudent to think about where that scattered money is going...
Darling Darlin Darlin you got the love i need.
TLTFF the FDAs new Darlin.
Q4 2020 newsletter was released Feb 1, 2021
FEB 1 2021 Was About 32 Days After Q42020 Data Collection Time Period.
Theralase® Announces Leadership Reorganization
Toronto, Ontario – November 15, 2021
Perhaps this new Reorganization will include consistent reporting on the Q4 Quarterly for this year as well. People might just have to say the new management team got it out timely.
Theralase Releases Quarterly Newsletter Toronto, Ontario – February 01, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...
$TLTFF-FULLY FUNDED -The Company successfully completed an oversubscribed marketed public offering on August 22, 2019, raising gross proceeds of CAD $17,250,000, fully funded for Phase II NMIBC Clinical Study.
Analyst Coverage Mackie Research Capital Echelon Wealth Partners Target Price “$0.80” by Mackie Research “$0.50” by Echelon Wealth
TREATMENT FOR VARIOUS CANCERS Planning on initiating Phase 1b study for other cancer indications. Strong upside for growth and valuation.
PowerPoint Presentation Sept 2021
#CathieWood
#ARKK Invest Holdings
$TLTFF-PH2DATA BTD INPROGRESS
Cathie Wood would you care to look at the data for Theralase Phase 2 study?
Theralase Releases 3Q21 Financial Statements and Newsletter
Toronto, Ontario – November 29, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses has released the Company’s unaudited 3Q2021 condensed interim consolidated Financial Statements (“Financial Statements”), which provides financial information on the previous fiscal quarter and the quarterly Newsletter (“Newsletter”) which provides an interim clinical data analysis on the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) clinical study (“Study II”).
The Financial Statements can be found on the Company’s Website at www.theralase.com/financial-filings/
The Newsletter can be found on the Company’s website at tHERALASE QUARTER NEWSLETTER
Not a dollar yet but a great read Ma'am
They will get data points and the chase will be on.
Buy now or chase later.
The money is a much lesser an issue than the tech development.
Look to the actions and money supplied by the Canadian Government.
They understand the data and it's market value. That's why they are putting up millions for PDT.
Thats why the analysis said that in one of his posts.
They are already crossing the threshold.
Theralase Researchers Receive Government Grant 2018 4.5mil
Don't ya kinda thnk the patients for this funding are getting treated currently???
And how many could you treat for 4.5 million?? Enough patients for the study completion may be a good starting point for consideration.
Yes...
DD DD DD
Theralase Researchers Receive Government Grant 2018 4.5mil
University Health Network (“UHN”) and the University of Toronto (“UT”) have received an Ontario Research Fund – Research Excellence (“ORF-RE”) grant with a primary mandate of advancing personalized Anti-Cancer Photo Dynamic Therapy (“PDT”) for each individual cancer patient to safely and effectively destroy their particular cancer, while maintaining the highest possible quality of life for them.
123414 ok...i get it. you don't really want to engage my questions. but recognize that as things stand and until new results reasonably meet current high expectations and/or 1 or better 2 potential JV partners show up (2 gives better leverage for deals), TLT just doesn't have huge bargaining leverage with funders. And at current burn rate, TLT has approx. 10 months of $$. Some, but not that much time. So...while management will likely wait 'til next 1/4's hopefully very positive news to tackle the funding question in earnest, if they are smart -- and I hope they are smarter than the last funding -- they have to be at least researching funding alternatives.
And I disagree that they are doing enough to get their story out to potential investors. At the 2 quarterly conf calls, they couldn't even get it together to take questions from shareholders. Good comm is not their strong point, IMHO. But hopefully, good science is !! If yes, the funding alternatives will likely open up quite a bit.
Digits very crossed for all concerned !!
Fwiw, no need to respond to this with more recent positive news items. Have followed very closely over the years...and have recently added to my position. There has been ton of positive developments, I grant you and that's great. But again...I hope TLT has some reasonable plan b's lined up. Just in case. Nothing can be assumed... until it proves out imo.
MILLIONS IN THE BANK- TINY BURNRATE
Plenty of friendlies all around.
Some friendly suitors for the tech. yep...
Eyes are already here....
3,379,146CAD / 9 months =CAD 375,460.00 monthly BURNRATE
"I am honored to return as the Interim CEO for the Company, as the Company
realigns its executive management team to focus on the Company’s primary
objective of commercialization of its ACT technology, which, if successful, will ultimately deliver shareholder value."
Dr Arkady Mandel
Interim CEO & CSO, Theralase®
Theralase® Announces Leadership Reorganization
Toronto, Ontario – November 15, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today the following leadership reorganization:
Effective November 15, 2021, Dr. Arkady Mandel, M.D., Ph.D., D.Sc., who is currently the Chief Scientific Officer (“CSO”) of the Company, will assume the role of Interim Chief Executive Officer (“CEO”), replacing Mr. John Trikola in the role of Interim CEO of the Company.
Mr. Trikola has agreed to resign from his positions as the Chief Operating Officer and Interim CEO of the Company effective immediately, as a result of certain facts that have come to the Company’s attention concerning Mr. Trikola’s background that the Company’s vetting process failed to detect. The Company is currently taking steps to improve its vetting process for incoming officers and directors.
Effective October 25, 2021, Dr. Vera Madzarevic, Ph.D. will assume the role of Director of Clinical Development and Quality Assurance reporting to Dr. Mandel.
Dr. Madzarevic holds a Ph.D. in both clinical pharmacology and biochemistry and brings over 25 years of global experience in clinical research and quality assurance in the biopharmaceutical and medical device industry to Theralase®.
For the last 20 years, Dr. Madzarevic has been the Global Director, Clinical Research Services and Medical Affairs for Global Research Pharma Canada, a contract Clinical Research Organization (“CRO”), where she was involved in all phases of clinical development (Phase I to IV), training, product development, strategic planning and for implementing, monitoring and managing clinical and scientific activities for clients worldwide.
Prior to this appointment, she was employed as a senior clinical research scientist for Novartis Pharmaceuticals based in New Jersey, USA.
Dr. Madzarevic, appointed Director of Clinical Development and Quality Assurance at Theralase® stated, “It is a pleasure to join the Theralase® clinical research team, reporting to Dr. Mandel. I feel my extensive global experience in clinical research and quality assurance will support the Company’s primary objective of successfully developing with the objective of commercializing its Anti-Cancer Therapy (“ACT”) technology.”
Dr. Mandel, CSO and Interim CEO of Theralase® stated, “I am honored to return as the Interim CEO for the Company, as the Company realigns its executive management team to focus on the Company’s primary objective of commercialization of its ACT technology, which, if successful, will ultimately deliver shareholder value.”
Mr. Matthew Perraton, Chairman of the Board of Directors of Theralase® stated, “On behalf of the Board of Directors, we believe that Dr. Madzarevic will be a great addition to the Company in the role of Director of Clinical Development and Quality Assurance and we welcome her to the clinical team. This reorganization in leadership allows Dr. Mandel to assume the role of Interim CEO and devote attention to the successful commercialization of our ACT technology for Non-Muscle Invasive Bladder Cancer (“NMIBC”), as well as other oncological conditions, such as Glio Blastoma Multiforme (“GBM”) and Non-Small Cell Lung Cancer (“NSCLC”).”
2021 NEWSLETTER RELEASED FEBUARY 1 2021
Theralase Releases Quarterly Newsletter
Toronto, Ontario – February 01, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...
Research Capital analyst André Uddin is sticking with his “Speculative Buy” rating on drug and device developer Theralase Technologies (Theralase Technologies Stock Quote, Charts, News, Analysts, Financials TSXV:TLT) after the company’s latest earnings report. In an update to clients on Tuesday, Uddin said time will tell how Theralase’s lead photodynamic compound, TLD-1433, compares with Merck’s immunotherapy Keytruda.
Toronto-based Theralase has a legacy business in marketing cool laser therapy devices for pain and inflammation management and is currently focused on developing its photodynamic therapy for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
The company released its second quarter financials on Tuesday, showing total revenue up 47 per cent year-over-year to $430,000 with a net loss of $2.1 million compared to a loss of $3.3 million a year ago. Theralase ended the quarter with $5.9 million in cash and zero debt.
Theralase attributed the top-line gain to the impact of COVID-19 last year where healthcare practitioners had closed offices and put orders for the company’s cool laser devices on temporary or permanent hold. The lower net loss was chalked up to a delay in patient enrolment and treatment for its Phase 2 NMIBC clinical study due to COVID 19 along with decreased salaries due to COVID-19, resulting in the loss (resignation or termination) of administrative, research and production personnel).
Theralase had a leadership shake-up recently with the departure of CEO Shawn Shirazi on August 20, with John Trikola, recent president of Gardner Ross Corp., taking on the positions of COO and Interim CEO.
“I am honored to join Theralase as the COO and Interim CEO. I have developed a deep appreciation for what makes Theralase so special and I believe the Company has tremendous opportunities in front of it to capitalize on the innovation and technological advancements that the Company has demonstrated to date. I look forward to working with all stakeholders to enhance the buyer experience and provide additional capabilities that will help health care practitioners sustain and grow their businesses. I will focus on continuing to evolve the Company’s strategy while delivering on Theralase’s commitment to maximizing long-term shareholder value,” said Trikola in an August 19 press release.
On the NMIBC study, Theralase said it has five clinical study sites now launched in Canada and seven in the United States for patient enrolment and treatment, for a total of 12 sites. So far, the study has provided primary study treatment for 24 patients including three from the Phase 1b study treated at the Therapeutic Dose for a total of 27.
On the preliminary results, Theralase said,
“The current interim analysis of the clinical data (with significant clinical data still pending and based on only 27 patients) demonstrates that Study II’s primary (33.3 per cent) and tertiary objectives (1 Severe AE) demonstrate a strong initial efficacy, strong durable efficacy and a high safety profile. There is insufficient data to comment on the Study II secondary objective,” the company stated in the August 30 press release.
Commenting on the quarter and preliminary results, Uddin said with the TLD-1433 still in Phase 2, financials are less important for TLT at the moment.
On the Phase 2 study, Uddin said, “TLT reported an interim analysis across a treatment period of 450 days based on the 24 subjects and three subjects from the previous Phase 1b trial treated at the therapeutic dose. At 90 days of treatment, 33.3 per cent of the 27 subjects (nine) achieved CR, which decreased to 18.5 per cent (5) at 270 days and 11.1 per cent (3) at 360 days. We believe what is most important with this preliminary dataset is that at 270 & 360 days, there were 37.0 per cent (10) and 40.7 per cent (11) of the 27 subjects which had not received both doses of TLD-1433.”
On the comparison with Merck’s Keytruda, which has been approved for BCG-unresponsive NMIBC and has achieved a 19 per cent complete response at 12 months of treatment in the pivotal KEYNOTE-057 study, Uddin wrote,
“For the 27 subjects in TLT’s pivotal trial to achieve the same CR rate at 360 days as Keytruda, an additional three subjects out of the 11 which had not received both doses of TLD-1433 would need to achieve CR – representing a 27 per cent threshold (3/11) – we believe this is a feasible threshold for Theralase given the data presented to date,” Uddin said.
“As the Phase 2 pivotal trial continues to progress, we believe the results should elucidate the efficacy potential of TLT-1433. We are maintaining our SPECULATIVE BUY rating and a target price of $0.70,” Uddin wrote.
Uddin also commented on a recent event from competitor Sesen Bio, which on August 13 received a complete response letter (CRL) from the US FDA on a BLA for its Vicineum in BCG- unresponse NMIBC. Uddin related that Sesen aims to meet with the FDA in the fourth quarter of this year to get better clarity on next steps. The analyst said the announcement could open a potential window of opportunity for TLT, saying,
“On August 18th, a report by STAT News, which was based on SESN’s internal documents obtained by STAT, stated SESN’s pivotal trial with Vicineum had thousands of violations of study rules, investigator misconduct and worrying signs of toxicity SESN did not publicly disclose,” Uddin wrote.
At press time, Uddin’s $0.70 target represented a projected one-year return of 233 per cent.
Sept 1 2021 Research Capital RE: Theralase 2021https://www.cantechletter.com/2021/09/theralase-technologies-has-a-233-per-cent-upside-says-research-capital/#
$TLTFF - Bullish at twice the market cap in value.
$TLTFF Blue sky breakout BTD Toppling data.
not sure, but i think you may be “floatinkentucky” from stockhouse board. either way, i agree with your excitement about TLT’s science. i’ve been a shareholder for many years and it all is feeling closer and closer.
that said — and i may get some boos — i have concerns re tlt’s finances. they have maybe 3m remaining but unless pps rises enough for people to exercise warrants and being in cash, tlt must already be making plans to raise needed funds to continue. longtimers know how tlt imho botched their last funding… so to me it’s a real concern. so is company’s general lack of outreach to the investing community to get their amazing story out there. generally, that doesn’t just happen by itself. if you’re up to it, pls consider contacting Kristina Hachey to let her know the story needs more telling!
like so many i dearly hope our next quarterly report brings great results and a commensurate rise in pps and warrant redemptions. expectations are high but pps in hold pattern lately. if news disappoints, stock will sell off in this lousy market. so…i’d sure like to know what TLT’s plan b is in case needed….
any thoughts?
pls feel free to post on stockhouse i am not a subscriber there
$TLTFF Photo Dynamic Compound Inactivation of SARS-CoV-2 Vaccine
Under the terms of the agreement, Theralase® and Public Health Agency of Canada PHAC are collaborating on the development and optimization of a COVID-19 vaccine by treating the SARS-CoV-2 virus grown on cell lines with Theralase®’s patented PDC and then light activating it with Theralase®’s proprietary TLC-3000A light technology to inactivate the virus and create the fundamental building blocks of a COVID-19 vaccine. This inactivated virus would then be purified and used to inoculate naive animals followed by challenge with the SARS-CoV-2 virus, to ascertain the efficacy of the vaccine. The project is entitled, “Photo Dynamic Compound Inactivation of SARS-CoV-2 Vaccine” and is expected to commence in mid-April 2021.
Theralase Releases Quarterly Newsletter February 01, 2021
Last year it came out on February 1st.
#jimcrammer $TLTFF Ph 2 pivotal toppling data-BTD
Sounds like good science..
It is difficult for small time investors away from the source to validate the results of the science. As much, great trepidation exists and holds the price down with little interest in the unknown...
That said.. I have my bet placed... cuz if this science gets validated and approved for clinical use I might not be able to afford shares..
This is the reason why bio-techs rocket off the starting line. A new technology appears out of nowhere that alters the related landscape. For a visual reference, the Tonga Volcano comes to mind.
This is why I have some chips on the table.
Additional Theralase cancer research
Theralase Lead Anti-Cancer Drug Effective in the Destruction of Throat Cancer
Toronto, Ontario – September 19, 2017
Theralase® Anti-Cancer Vaccine Validated in Colorectal Cance
November 22, 2017
Theralase® Advances Anti-Cancer Technology in Destruction of Human Lung Cancer
Toronto, Ontario – March 5, 2018
Theralase® Discovers Cannabinoid Increases Efficacy of Patented Anti-Cancer Technology in Destruction of Brain Cancer
Toronto, Ontario – March 27, 2018
$TLTFF Good morning. Let's have a good day.
TLT has an 8 year base at least . Biggest market winners always have that in common .
Longer the base bigger the price .
Potential Drive to .45 USD
Price calculated from trendline monthly chart Plots and company's latest phase 2 study CR rates:
Highs for August 2017
April 2019.
Expectation:
Market response similar to Monthly Chart period Nov 2016 through Aug 2017.
This current price level on the Ten-year Month,
is a historical point where sometimes the company sp really jumps up from these levels. Provided the company is making progress in their business plans. And they are.
if you consider the range the stock has held for so many years that is well above the current price point.
You might consider the market assessed the stock to be worth the SP at that time. And this was before they were approved for a Phase 2 study and before they had the data points that are unprecedented.
Before PHAC and St. Michaels.
So for me I see the value.
_________________________________________________
The hard and long fall from March 2019.
At the closing of the phase one study buyers were looking for the next business development and it was a long way out. The price fall began in March. Other investors soon realized how far out the next significant steps would be taken for Phase 2 Pivotal. And the market forces propelled.
The market forces are again propelling in the opposite.
______________________________________________________
TORONTO, ON / ACCESSWIRE / January 31, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient five, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study ("Study"), has demonstrated no tumour recurrence or presence of disease at the 360 day clinical and cystoscopy assessment.
The Study's purpose was to evaluate TLD-1433, Theralase's lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment.
The Study was successfully completed with patient five and six demonstrating achievement of the primary, secondary and exploratory endpoints.
Patient five has demonstrated no tumour recurrence or presence of disease at the 90, 180, 270 and now 360 days post treatment clinical and cystoscopy assessment, marking a new achievement for the Company.
Patients five and six were enrolled and treated in the Study at the Therapeutic Dose (0.70 mg/cm2). Theralase's Anti-Cancer Treatment involved the intravesical instillation of a water-based solution of Theralase's lead anti-cancer PDC, TLD-1433, via a catheter inserted through the urethra into the bladder of the patient, to allow the PDC to be preferentially absorbed by NMIBC tumours. The bladder was then drained of the solution, flushed with sterile water to remove non-absorbed solution and refilled with sterile water via a cystoscope. A fibre optic assembly, comprising a Laser Emitter used to emit laser light and a proprietary Dosimetry System used to detect laser light, were then used to activate TLD-1433 resident in the NMIBC tumours.
------------------------------------------------
Monthly Chart Nov 2019 to present
Large down gaps, monthly chart 2019 July & August
Large up gaps, monthly chart 2021 Nov & Dec
2019 July Monthly High .3920 Low .2370
2019 August Monthly High .2609 Low .1636
2019 August Monthly gap filled - 2021 November
2021 November Monthly Low .1366 High . 2206
July 2019 Monthly Down gap fill in progress - Dec 2021.
2021 December Monthly Low .1950 High . 2989
Current .259
----------------------------------------------
https://theralase.com/theralase-releases-3q21-financial-statements-and-newsletter/
Study II Preliminary Results
As of November 29, 2021, Study II has enrolled and provided the primary study treatment for 30 patients (including three patients from the Study treated at the Therapeutic Dose) for a total of 33 patients, demonstrating the following interim results:
Note: Significant clinical data is still pending in Study II and drawing conclusions from this interim clinical data set and assumptions should be done with caution, as Study II is still ongoing and new clinical data collected may or may not continue to support the current trend.
*Includes three (3) patients treated at the Therapeutic Dose form Phase Ib NMIBC Clinical Study (2-CR and 1- NR at 90, 180, 270, 360, 450 days)
An analysis of the Study II clinical data (with 3 patients from Study Ib) provides the following interim assessments:
7/10 patients (70.0%), who achieved a CR at 90 days continue to demonstrate CR at 180 days
In the total population of 33 patients (@ 90 days):
42.4% achieved Complete Response (“CR”)
12.1% achieved Partial Response (“PR”)
21.2% are Pending
24.2% achieved No Response (“NR”)
Hence, the potential for CR is up to 75.8%** for the interim clinical data analysis.
Note**: Assumes both PR and Pending data are clinically determined to be CR at a later assessment date.
In the total population of 18 patients (@ 90 days), who received the optimized treatment:
44.4% achieved CR
11.1% achieved PR
38.9% are Pending
5.6% achieved NR
Hence, the potential for CR is up to 94.4%***
Theralase warrants trade in the open market increasing the strike price.
https://stockhouse.com/companies/quote?symbol=v.tlt.w
Theralase Technologies Inc. V.TLT.W
Primary Symbol: V.TLT Alternate Symbol(s): TLTFF
Healthcare
Theralase Technologies Inc is a clinical stage pharmaceutical company. It is dedicated to the research and development of light activated Photo Dynamic Compounds, their associated drug formulations and technology platforms intended to safely and effectively; treat various cancers, bacteria and viruses. The Cool Laser Technology division designs, develops, manufactures and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, primarily in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.
$0.215Bid: 0.195 x 19500Ask: 0.225 x 1500Volume: 0
CADTSX VENTURE EXCHANGEDELAYED PRICEJANUARY 7, 2022 3:44 PMEST
NUMBER OF COMMON SHARES OUTSTANDING
Share Price: C$0.14
Warrants: 72,473,931
Shares Outstanding: 204,275,375
Stock Options: 14,500,000
Fully Diluted: 291,249,306
https://theralase.com/invest/
When they stop selling cheap.
What are you going to do??
Meghan,
Float is his other alias from another board, that we frequent.
The $B reference is to show what the SP would be if the company were valued at $1B. So for every $1B, offered if there was a buyout then the SP would need to reach approx $3.43.
Nice to hear from you.
Good luck to all. Regards,BK
Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine
April 9, 2021
Megan in my view, the study has already been Improved. After the "dirty dozen" were undertreated the treatment protocol was returned to the Ph 1 67% cr study protocol. So patients 13 -30 got the proper dose and that info is now just showing up in the pr data.
The last batch of data released has now confirmed the improvements made directly after the first treated 12 patients from phase 2 has bore fruit.
And is currently at unprecedented levels of Cr with exception to the Theralse Phase 1 study. In other words no one beats Theralase rates now except Theralase phase 1 study.
And in this study each patients gets two treatments (each treatment about 6 months apart). The phase one study patients only received one treatment.
Some undertreated patients will get a full dose for sure!
https://theralase.com/wp-content/uploads/2021/11/3Q-2021-Newsletter.pdf
204 million Outstanding.. re:BK
Your quote..
"Hi Float:
1000/291.250 approx. 3.43B
I just couldn't remember the exact numbers and used an approximation.
Good to hear from you.
Good luck to all. Regards,BK"
From what I can see
192 Million in the float.
Not sure where the billions reference comes from?
https://www.barrons.com/market-data/stocks/tltff
https://www.marketwatch.com/investing/stock/tltff
https://www.wsj.com/market-data/quotes/TLTFF
What if Theralase has solved the cancer riddle? Taking a position at .28 cents will look like pure genius if Phase II is improved upon and duplicated working with our new research partners.
https://theralase.com/theralase-launches-anti-cancer-therapy-research-centre/
This is a catching lightning situation.
Hi Float:
1000/291.250 approx. 3.43B
I just couldn't remember the exact numbers and used an approximation.
Good to hear from you.
Good luck to all. Regards,BK
#JIMCRAMMER $TLTFF-PH2DATA
Mr. Crammer would you care to look at the data for Theralase Phase 2 study?
TLTFF Theralase TechnologiesTheralase Releases 3Q21 Financial Statements and Newsletter
$TLTFF #JIMCRAMMER
Mr. Crammer would you care to look at the data for Theralase Phase 2 study?
$TLTFF an additional three subjects out of the 11 without 2dose
Published Sept 1, 2021
On the Phase 2 study, Uddin said, “TLT reported an interim analysis across a treatment period of 450 days based on the 24 subjects and three subjects from the previous Phase 1b trial treated at the therapeutic dose. At 90 days of treatment, 33.3 per cent of the 27 subjects (nine) achieved CR, which decreased to 18.5 per cent (5) at 270 days and 11.1 per cent (3) at 360 days. We believe what is most important with this preliminary dataset is that at 270 & 360 days, there were 37.0 per cent (10) and 40.7 per cent (11) of the 27 subjects which had not received both doses of TLD-1433.”
On the comparison with Merck’s Keytruda, which has been approved for BCG-unresponsive NMIBC and has achieved a 19 per cent complete response at 12 months of treatment in the pivotal KEYNOTE-057 study, Uddin wrote,
“For the 27 subjects in TLT’s pivotal trial to achieve the same CR rate at 360 days as Keytruda, an additional three subjects out of the 11 which had not received both doses of TLD-1433 would need to achieve CR – representing a 27 per cent threshold (3/11) – we believe this is a feasible threshold for Theralase given the data presented to date,” Uddin said.
“As the Phase 2 pivotal trial continues to progress, we believe the results should elucidate the efficacy potential of TLT-1433. We are maintaining our SPECULATIVE BUY rating and a target price of $0.70,” Uddin wrote.
Uddin also commented on a recent event from competitor Sesen Bio, which on August 13 received a complete response letter (CRL) from the US FDA on a BLA for its Vicineum in BCG- unresponse NMIBC. Uddin related that Sesen aims to meet with the FDA in the fourth quarter of this year to get better clarity on next steps. The analyst said the announcement could open a potential window of opportunity for TLT, saying,
“On August 18th, a report by STAT News, which was based on SESN’s internal documents obtained by STAT, stated SESN’s pivotal trial with Vicineum had thousands of violations of study rules, investigator misconduct and worrying signs of toxicity SESN did not publicly disclose,” Uddin wrote.
At press time, Uddin’s $0.70 target represented a projected one-year return of 233 per cent.
https://www.cantechletter.com/2021/09/theralase-technologies-has-a-233-per-cent-upside-says-research-capital/#
This stock can be very frustrating. Has gone for long periods of time without much movement. But now there's science and proof of lab performance on patients, which this last quarterly confirmed.
This is highly speculative, but the prior lab/petre dish tests are getting proven on patients.
I wanted to inform everyone prior to the next quarterly report which should be late October from the Sept 30 EOQ period. If that report continues to provide patient data that extends the CR in patients that have been treated, and exhibits high CR performance on new patients that have 90 performance data - I don't know what affect that may have. It's all new information.
This is a cure for 1 type of cancer. It has practical applications for many other types that have gone through the same lab vetting process to check for efficacy. It's been reviewed for melanoma, brain cancer and Non-small cell lung cancer.
Someone asked what's the expected sp target? Every increment of $3.50 is approximately $1B in MC. What's a cure for cancer worth? And now Health Canada is testing in their Level4 Microbio Lab for Covid, SARS, and other viruses. What's that worth?
I can't tell how many people, or funds will pile in. I'm thinking this is a $50-$100 stock, which puts at approx. $14B-$28B. But, something else is telling me that investors want to be on the right side of an investment, and this is so far beyond Amazon, FB or Google.
Good luck to all. Regards,BK.
----------------------------------------
Hello BIGKAHUNA57 how did you get your Market cap est?
Followers
|
81
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4159
|
Created
|
01/20/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |